公开(公告)号：US6043230A

公开(公告)日：2000-03-28

申请号：US314606

申请日：1999-05-19

申请人： Murty N. Arimilli ,  Kenneth C. Cundy ,  Joseph P. Dougherty ,  Choung U. Kim ,  Reza Oliyai ,  Valentino J. Stella

发明人： Murty N. Arimilli ,  Kenneth C. Cundy ,  Joseph P. Dougherty ,  Choung U. Kim ,  Reza Oliyai ,  Valentino J. Stella

IPC分类号： C07F9/6512 ,  C07F9/6561 ,  A61K31/675

CPC分类号： C07F9/65616 ,  C07F9/65121

摘要： Novel compounds are provided that comprise esters of antiviral phosphonomethoxy nucleotide analogs with carbonates and/or carbamates having the structure -OC(R.sup.2).sub.2 OC(O) X(R).sub.a, wherein R.sup.2 independently is H, C.sub.1 -C.sub.12 alkyl, aryl, alkenyl, alkynyl, alkyenylaryl, alkynylaryl, alkaryl, arylalkynyl, arylalkenyl or arylalkyl which is unsubstituted or is substituted with halo, azido, nitro or OR.sup.3 in which R.sup.3 is C.sub.1 -C12 alkyl; X is N or O; R is independently H, C.sub.1 -C.sub.12 alkyl, aryl, alkenyl, alkynyl, alkyenylaryl, alkynylaryl, alkaryl, arylalkynyl, arylalkenyl or arylalkyl which is unsubstituted or is substituted with halo, axido, nitro, --O--, --N.dbd., --NR.sup.4 --, --N(R.sup.4).sub.2 -- or OR.sup.3, R.sup.4 independently is --H or C.sub.1 -C.sub.8 alkyl, provided that at least one R is not H; and a is 1 or 2, with the proviso that when a is 2 and X is N, (a) two R groups can be taken together to form a carbocycle or oxygen-containing heterocycle, or (b) one R additionally can be OR.sup.3. The compounds are useful as intermediates for the preparation of antiviral compounds or oligonucleotides, or are useful for administration directly to patients for antiviral therapy or prophylaxis. Embodiments are particularly useful when administered orally.

摘要翻译： 提供新的化合物，其包含抗病毒膦基甲氧基核苷酸类似物与具有结构-OC（R 2）2 OC（O）X（R）a的碳酸酯和/或氨基甲酸酯的酯，其中R2独立地为H，C1-C12烷基，芳基，烯基 炔基，烷基芳基，炔基芳基，烷芳基，芳基炔基，芳基烯基或芳烷基，其未被取代或被卤素，叠氮基，硝基或OR 3取代，其中R 3是C 1 -C 12烷基; X为N或O; R是独立的H，C 1 -C 12烷基，芳基，烯基，炔基，链烯基芳基，炔基芳基，烷芳基，芳基炔基，芳基烯基或芳基烷基，其未被取代或被卤素，轴酰基，硝基，-O - ， - N = - ， - N（R4）2-或OR3，R4独立地是-H或C1-C8烷基，条件是至少一个R不是H; 和a为1或2，条件是当a为2且X为N时，（a）两个R基团可以一起形成碳环或含氧杂环，或（b）一个R另外可以是OR 3 。 该化合物可用作制备抗病毒化合物或寡核苷酸的中间体，或可用于直接给患者施用抗病毒治疗或预防。 当口服给药时，实施方案特别有用。

公开(公告)号：US6069249A

公开(公告)日：2000-05-30

申请号：US314607

申请日：1999-05-19

申请人： Murty N. Arimilli ,  Kenneth C. Cundy ,  Joseph P. Dougherty ,  Choung U. Kim ,  Reza Oliyai ,  Valentino J. Stella

发明人： Murty N. Arimilli ,  Kenneth C. Cundy ,  Joseph P. Dougherty ,  Choung U. Kim ,  Reza Oliyai ,  Valentino J. Stella

IPC分类号： C07F9/6512 ,  C07F9/6561

CPC分类号： C07F9/65616 ,  C07F9/65121

摘要： Novel compounds are provided that comprise esters of antiviral phosphonomethoxy nucleotide analogs with carbonates and/or carbamates having the structure --OC(R.sup.2).sub.2 OC(O)X(R).sub.a, wherein R.sup.2 independently is H, C.sub.1 -C.sub.12 alkyl, aryl, alkenyl, alkynyl, alkyenylaryl, alkynylaryl, alkaryl, arylalkynyl, arylalkenyl or arylalkyl which is unsubstituted or is substituted with halo, azido, nitro or OR.sup.3 in which R.sup.3 is C.sub.1 -C.sub.12 alkyl; X is N or O; R is independently H, C.sub.1 -C.sub.12 alkyl, aryl, alkenyl, alkynyl, alkyenylaryl, alkynylaryl, alkaryl, arylalkynyl, arylalkenyl or arylalkyl which is unsubstituted or is substituted with halo, azido, nitro, --O--, --N.dbd., --NR.sup.4 --, --N(R.sup.4).sub.2 -- or OR.sup.3, R.sup.4 independently is --H or C.sub.1 -C.sub.8 alkyl, provided that at least one R is not H; and a is 1 or 2, with the proviso that when a is 2 and X is N, (a) two R groups can be taken together to form a carbocycle or oxygen-containing heterocycle, or (b) one R additionally can be OR.sup.3. The compounds are useful as intermediates for the preparation of antiviral compounds or oligonucleotides, or are useful for administration directly to patients for antiviral therapy of prophylaxis. Embodiments are particularly useful when administered orally.

摘要翻译： 提供新的化合物，其包含抗病毒膦基甲氧基核苷酸类似物与具有结构-OC（R 2）2 OC（O）X（R）a的碳酸酯和/或氨基甲酸酯的酯，其中R2独立地为H，C1-C12烷基，芳基，烯基 炔基，烷基芳基，炔基芳基，烷芳基，芳基炔基，芳基烯基或芳烷基，其未被取代或被卤素，叠氮基，硝基或OR 3取代，其中R 3是C 1 -C 12烷基; X为N或O; R是独立的H，C 1 -C 12烷基，芳基，烯基，炔基，链烯基芳基，炔基芳基，烷芳基，芳基炔基，芳基烯基或芳烷基，其未被取代或被卤素，叠氮基，硝基，-O - ， - N = - ， - N（R4）2-或OR3，R4独立地是-H或C1-C8烷基，条件是至少一个R不是H; 和a为1或2，条件是当a为2且X为N时，（a）两个R基团可以一起形成碳环或含氧杂环，或（b）一个R另外可以是OR 3 。 该化合物可用作制备抗病毒化合物或寡核苷酸的中间体，或者可用于直接给患者预防用于抗病毒治疗的患者。 当口服给药时，实施方案特别有用。

公开(公告)号：US5977089A

公开(公告)日：1999-11-02

申请号：US187763

申请日：1998-11-06

申请人： Murty N. Arimilli ,  Kenneth C. Cundy ,  Joseph P. Dougherty ,  Choung U. Kim ,  Reza Oliyai ,  Valentino J. Stella

发明人： Murty N. Arimilli ,  Kenneth C. Cundy ,  Joseph P. Dougherty ,  Choung U. Kim ,  Reza Oliyai ,  Valentino J. Stella

IPC分类号： C07F9/6512 ,  C07F9/6561 ,  A61K31/675

CPC分类号： C07F9/65616 ,  C07F9/65121

摘要： Compounds are provided that comprise esters of antiviral phosphonomethoxy nucleotide analogs with carbonates and/or carbamates having the structure --OC(R.sup.2).sub.2 OC(O)X(R).sub.a, wherein R.sup.2 independently is H, C.sub.1 -C.sub.12 alkyl, aryl, alkenyl, alkynyl, alkyenylaryl, alkynylaryl, alkaryl, arylalkynyl, arylalkenyl or arylalkyl which is unsubstituted or is substituted with halo, azido, nitro or OR.sup.3 in which R.sup.3 is C.sub.1 -C.sub.12 alkyl; X is N or O; R is independently H, C.sub.1 -C.sub.12 alkyl, aryl, alkenyl, alkynyl, alkyenylaryl, alkynylaryl, alkaryl, arylalkynyl, arylalkenyl or arylalkyl which is unsubstituted or is substituted with halo, azido, nitro, --O--, --N.dbd., --NR.sup.4 --, --N(R.sup.4).sub.2 -- or OR.sup.3, R.sup.4 independently is --H or C.sub.1 -C.sub.8 alkyl, provided that at least one R is not H; and a is 1 or 2, with the proviso that when a is 2 and X is N, (a) two R groups can be taken together to form a carbocycle or oxygen-containing heterocycle, or (b) one R additionally can be OR.sup.3. The compounds are useful as intermediates for the preparation of antiviral compounds or oligonucleotides, or are useful for administration directly to patients for antiviral therapy or prophylaxis. Embodiments are particularly useful when administered orally.

摘要翻译： 提供了包含具有结构-OC（R 2）2 OC（O）X（R）a的碳酸酯和/或氨基甲酸酯的抗病毒膦基甲氧基核苷酸类似物的酯的化合物，其中R2独立地是H，C1-C12烷基，芳基，烯基， 炔基，烷基芳基，炔基芳基，烷芳基，芳基炔基，芳基烯基或芳基烷基，其未被取代或被卤素，叠氮基，硝基或OR 3取代，其中R 3是C 1 -C 12烷基; X为N或O; R是独立的H，C 1 -C 12烷基，芳基，烯基，炔基，链烯基芳基，炔基芳基，烷芳基，芳基炔基，芳基烯基或芳烷基，其未被取代或被卤素，叠氮基，硝基，-O - ， - N = - ， - N（R4）2-或OR3，R4独立地是-H或C1-C8烷基，条件是至少一个R不是H; 和a为1或2，条件是当a为2且X为N时，（a）两个R基团可以一起形成碳环或含氧杂环，或（b）一个R另外可以是OR 3 。 该化合物可用作制备抗病毒化合物或寡核苷酸的中间体，或可用于直接给患者施用抗病毒治疗或预防。 当口服给药时，实施方案特别有用。

公开(公告)号：USRE38333E1

公开(公告)日：2003-11-25

申请号：US10159888

申请日：2002-05-29

申请人： Murty N. Arimilli ,  Kenneth C. Cundy ,  Joseph P. Dougherty ,  Choung U. Kim ,  Reza Oliyai ,  Valentino J. Stella

发明人： Murty N. Arimilli ,  Kenneth C. Cundy ,  Joseph P. Dougherty ,  Choung U. Kim ,  Reza Oliyai ,  Valentino J. Stella

IPC分类号： C07F96512

CPC分类号： C07F9/65616 ,  C07F9/6512

摘要： Novel compounds are provided that comprise esters of antiviral phosphonomethoxy nucleotide analogs with carbonates and/or carbamates having the structure —OC(R2)2OC(O)X(R)a, wherein R2 independently is H, C1-C12 alkyl, aryl, alkenyl, alkynyl, alkyenylaryl, alkynylaryl, alkaryl, arylalkynyl, arylalkenyl or arylalkyl which is unsubstituted or is substituted with halo, azido, nitro or OR3 in which R3 is C1-C12 alkyl; X is N or O; R is independently H, C1-C12 alkyl, aryl, alkenyl, alkynyl, alkyenylaryl, alkynylaryl, alkaryl, arylalkynyl, arylalkenyl or arylalkyl which is unsubstituted or is substituted with halo, azido, nitro, —O—, —N═, —NR4—, —N(R4)2— or OR3, R4 independently is —H or C1-C8 alkyl, provided that at least one R is not H; and a is 1 or 2, with the proviso that when a is 2 and X is N, (a) two R groups can be taken together to form a carbocycle or oxygen-containing heterocycle, or (b) one R additionally can be OR3. The compounds are useful as intermediates for the preparation of antiviral compounds or oligonucleotides, or are useful for administration directly to patients for antiviral therapy of prophylaxis. Embodiments are particularly useful when administered orally.

公开(公告)号：US5922695A

公开(公告)日：1999-07-13

申请号：US900746

申请日：1997-07-25

申请人： Murty N. Arimilli ,  Kenneth C. Cundy ,  Joseph P. Dougherty ,  Choung U. Kim ,  Reza Oliyai ,  Valentino J. Stella

发明人： Murty N. Arimilli ,  Kenneth C. Cundy ,  Joseph P. Dougherty ,  Choung U. Kim ,  Reza Oliyai ,  Valentino J. Stella

IPC分类号： C07F9/6512 ,  C07F9/6561 ,  A61K31/675

CPC分类号： C07F9/65616 ,  C07F9/65121

摘要： Novel compounds are provided that comprise esters of antiviral phosphonomethoxy nucleotide analogs with carbonates and/or carbamates having the structure --OC(R.sup.2).sub.2 OC(O)X(R).sub.a, wherein R.sup.2 independently is H, C.sub.1 -C.sub.12 alkyl, aryl, alkenyl, alkynyl, alkyenylaryl, alkynylaryl, alkaryl, arylalkynyl, arylalkenyl or arylalkyl which is unsubstituted or is substituted with halo, azido, nitro or OR.sup.3 in which R.sup.3 is C.sub.1 -C12 alkyl; X is N or O; R is independently H, C.sub.1 -C.sub.12 alkyl, aryl, alkenyl, alkynyl, alkyenylaryl, alkynylaryl, alkaryl, arylalkynyl, arylalkenyl or arylalkyl which is unsubstituted or is substituted with halo, azido, nitro, --O--, --N.dbd., --NR.sup.4 --, --N(R.sup.4).sub.2 -- or OR.sup.3, R.sup.4 independently is --H or C.sub.1 -C.sub.8 alkyl, provided that at least one R is not H; and a is 1 or 2, with the proviso that when a is 2 and X is N, (a) two R groups can be taken together to form a carbocycle or oxygen-containing heterocycle, or (b) one R additionally can be OR.sup.3. The compounds are useful as intermediates for the preparation of antiviral compounds or oligonucleotides, or are useful for administration directly to patients for antiviral therapy or prophylaxis. Embodiments are particularly useful when administered orally.

摘要翻译： 提供新的化合物，其包含抗病毒膦基甲氧基核苷酸类似物与具有结构-OC（R 2）2 OC（O）X（R）a的碳酸酯和/或氨基甲酸酯的酯，其中R2独立地为H，C1-C12烷基，芳基，烯基 炔基，烷基芳基，炔基芳基，烷芳基，芳基炔基，芳基烯基或芳烷基，其未被取代或被卤素，叠氮基，硝基或OR 3取代，其中R 3是C 1 -C 12烷基; X为N或O; R是独立的H，C 1 -C 12烷基，芳基，烯基，炔基，链烯基芳基，炔基芳基，烷芳基，芳基炔基，芳基烯基或芳烷基，其未被取代或被卤素，叠氮基，硝基，-O - ， - N = - ， - N（R4）2-或OR3，R4独立地是-H或C1-C8烷基，条件是至少一个R不是H; 和a为1或2，条件是当a为2且X为N时，（a）两个R基团可以一起形成碳环或含氧杂环，或（b）一个R另外可以是OR 3 。 该化合物可用作制备抗病毒化合物或寡核苷酸的中间体，或可用于直接给患者施用抗病毒治疗或预防。 当口服给药时，实施方案特别有用。

公开(公告)号：US06376393B1

公开(公告)日：2002-04-23

申请号：US09224044

申请日：1998-12-31

申请人： Mike Newton ,  Joseph P. Dougherty ,  Else Breval ,  Maria Klimkiewicz ,  Yi Ton Shi ,  Dean Arakaki

发明人： Mike Newton ,  Joseph P. Dougherty ,  Else Breval ,  Maria Klimkiewicz ,  Yi Ton Shi ,  Dean Arakaki

IPC分类号： H01L2131

CPC分类号： G06K9/00053 ,  A61B5/0531 ,  A61B5/1172

摘要： A method for making an anisotropic dielectric layer includes the steps of: forming a fluid layer comprising a plurality of magnetizable particles, for example, in a fluid capable of solidifying to fix the configuration of the magnetizable particles in a dielectric matrix; aligning the magnetizable particles of the fluid layer in a predetermined configuration by applying a magnetic field thereto; and fixing the aligned magnetizable particles in the predetermined configuration within the dielectric matrix by solidifying the fluid. In one particularly advantageous application, the fluid layer is coated onto a surface portion of an integrated circuit, such as a fingerprint sensor, to provide mechanical protection without effecting the image resolution. In addition, the step of aligning for certain devices preferably comprises aligning the magnetizable particles in a predetermined configuration so that an impedance perpendicular to the anisotropic dielectric layer is less than an impedance parallel to the anisotropic dielectric layer. The magnetizable particles may be mixed in a curable polymer fluid, and the step of fixing the aligned magnetizable particles may comprise curing the curable polymer fluid, such as by applying heat or radiation.

摘要翻译： 制造各向异性介电层的方法包括以下步骤：形成包含多个可磁化颗粒的流体层，例如在能够固化的流体中，将可磁化颗粒的构型固定在电介质基质中; 通过向其施加磁场来将流体层的可磁化颗粒对准预定构造; 以及通过固化所述流体将所述对准的可磁化颗粒固定在所述电介质基质内的所述预定构型中。 在一个特别有利的应用中，将流体层涂覆到诸如指纹传感器的集成电路的表面部分上，以提供机械保护而不影响图像分辨率。 此外，对于某些装置的对准步骤优选地包括以预定构型对准可磁化颗粒，使得垂直于各向异性介电层的阻抗小于平行于各向异性介电层的阻抗。 可磁化颗粒可以混合在可固化聚合物流体中，并且固定排列的可磁化颗粒的步骤可以包括固化可固化聚合物流体，例如通过施加热量或辐射。

公开(公告)号：US6022714A

公开(公告)日：2000-02-08

申请号：US574860

申请日：1995-12-19

申请人： Eugene L. Brown ,  Joseph P. Dougherty ,  Mary Collins

发明人： Eugene L. Brown ,  Joseph P. Dougherty ,  Mary Collins

IPC分类号： C07B61/00 ,  C07H21/00 ,  C12Q1/68 ,  C07H21/02 ,  C07H21/04 ,  C12P19/34

CPC分类号： C07H21/00 ,  C12Q1/6834 ,  C07B2200/11 ,  C40B40/00 ,  Y10S435/81

摘要： Compositions and methods for selectively linking a polynucleotide through its 5' or 3' end to one or more preselected materials such as insoluble matrices, solid supports, proteins, small molecular or labels are disclosed. Use of these compositions and methods in the production of diagnostic and affinity reagents are also disclosed.

摘要翻译： 公开了将多核苷酸通过其5'或3'端选择性连接到一种或多种预选物质如不溶性基质，固体支持物，蛋白质，小分子或标记物的组合物和方法。 还公开了这些组合物和方法在制备诊断和亲和试剂中的用途。

公开(公告)号：US5545184A

公开(公告)日：1996-08-13

申请号：US423500

申请日：1995-04-19

申请人： Joseph P. Dougherty

发明人： Joseph P. Dougherty

IPC分类号： A61N1/39

CPC分类号： A61N1/3956

摘要： A cardiac defibrillator which incorporates the invention hereof includes a multilayer capacitor with a plurality of conductive electrodes and interspersed dielectric layers, each dielectric layer composed of constituents which cause the dielectric layer to exhibit antiferroelectric characteristics. The defibrillator includes a charging circuit for applying to the capacitor an electric field across each dielectric layer that is at least equal to E.sub.f, where E.sub.f is a field value that enables the dielectric layer to transition to a ferroelectric phase. A preferred dielectric material comprises lead, lanthanum, zirconium and titanium, all at constituent values which cause the resulting ceramic material to lie within the antiferroelectric region.

摘要翻译： 结合本发明的心脏除颤器包括具有多个导电电极和散布电介质层的多层电容器，每个电介质层由使电介质层显示出反铁电特性的成分组成。 除颤器包括充电电路，用于向电容器施加横跨每个电介质层的至少等于Ef的电场，其中Ef是使电介质层能够转变到铁电相的场值。 一种优选的电介质材料包括铅，镧，锆和钛，全部以导致所得陶瓷材料位于反铁电区内的成分值。

公开(公告)号：US5391223A

公开(公告)日：1995-02-21

申请号：US110039

申请日：1993-08-20

申请人： Joseph P. Dougherty ,  Sea-Fue Wang ,  Wayne Huebner

发明人： Joseph P. Dougherty ,  Sea-Fue Wang ,  Wayne Huebner

IPC分类号： C04B41/51 ,  C04B41/88 ,  H01G4/008 ,  C23C20/04

CPC分类号： H01G4/008 ,  C04B41/5122 ,  C04B41/88

摘要： It has been newly determined that in a reaction of an Ag/Pd metallization with Pb from a lead-based ceramics, a maximum solubility of Pb is observed of approximately 14% (atomic percent). By inclusion of an effective amount of Pb in the Ag/Pd metallization, leaching of Pb from a Pb-based ceramic is either reduced or eliminated. Thus, upon firing, the metallization exhibits an equilibration which prevents Pb from being drawn out of the underlying ceramic. Similarly, Ag/Pd metallization shows a maximum solubility of 16 atomic percent for Bi in Bi-based ceramics. Inclusion of an effective amount of Bi in the metallization prevents a Bi leaching from an underlying ceramic.

摘要翻译： 新确定的是，在铅/铅金属化与铅基陶瓷的Pb反应中，Pb的最大溶解度约为14％（原子百分比）。 通过在Ag / Pd金属化中包含有效量的Pb，可以减少或消除Pb从Pb基陶瓷的浸出。 因此，在烧制时，金属化表现出平衡，防止Pb从下面的陶瓷中拉出。 类似地，Ag / Pd金属化显示Bi在Bi基陶瓷中的最大溶解度为16原子百分比。 在金属化中包含有效量的Bi防止来自底层陶瓷的Bi浸出。

公开(公告)号：US4818680A

公开(公告)日：1989-04-04

申请号：US811034

申请日：1985-12-18

申请人： Mary Collins ,  Joseph P. Dougherty ,  Marian S. Ellwood ,  Edward F. Fritsch ,  Kenneth A. Jacobs

发明人： Mary Collins ,  Joseph P. Dougherty ,  Marian S. Ellwood ,  Edward F. Fritsch ,  Kenneth A. Jacobs

IPC分类号： C12Q1/68 ,  G01N33/566

CPC分类号： C12Q1/6876 ,  C12Q1/6813 ,  C12Q1/6823 ,  Y10S435/81

摘要： A diagnostic reagent is disclosed which is capable of binding to a target nucleotide sequence which is bound to a labeled polynucleotide in a target binding region which is at least partially co-extensive with the target binding region in the probe polynucleotide which is capable of binding to the target nucleotide sequence. A method is disclosed in which the reagent is contacted with a sample and with a capturing polynucleotide under conditions such that target nucleotide which may be present in the sample binds to the probe polynucleotide and displaces labeled polynucleotide from the reagent complex, and the capturing polynucleotide binds selectively to the displaced labeled polynucleotide in the region of the labeled polynucleotide that had been bound to the probe polynucleotide. Determination of the displaced nucleotide gives a value which is a function of the presence and concentration of target nucleotide in the sample.

摘要翻译： 公开了一种诊断试剂，其能够结合靶向结合区域中的标记的多核苷酸的靶核苷酸序列，所述靶结合区域与探针多核苷酸中的靶结合区域至少部分共同扩增，所述靶结合区域能够结合 靶核苷酸序列。 公开了一种方法，其中试剂与样品和捕获多核苷酸在条件下接触，使得可能存在于样品中的靶核苷酸与探针多核苷酸结合并从试剂复合物置换标记的多核苷酸，并且捕获多核苷酸结合 选择性地与已经与探针多核苷酸结合的标记的多核苷酸的区域中的置换的标记的多核苷酸。 取代的核苷酸的测定给出一个值，该值是样品中靶核苷酸的存在和浓度的函数。